Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is androgen suppression therapy associated with early onset of fatal myocardial infarction?

Nature Clinical Practice Urology volume 5, pages 184–185 (2008)Cite this article

D'Amico AV et al. (2007) Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25: 2420–2425

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Bolla M et al. (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360: 103–106

    Article  CAS  Google Scholar 

  2. D'Amico AV et al. (2004) 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292: 821–827

    Article  CAS  Google Scholar 

  3. Wirth MP et al. (2004) Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 172: 1865–1870

    Article  CAS  Google Scholar 

  4. Keating NL et al. (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24: 4448–4456

    Article  CAS  Google Scholar 

  5. Saigal CS et al. (2007) Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110: 1493–1500

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. MG Sanda is an Associate Professor of Surgery at Harvard Medical School and Director at the Prostate Center at Beth Israel Deaconess Medical Center, Boston, MA ,

    Martin G Sanda

  2. M Kasibhatla is a Radiologist at the Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA.,

    Mohit Kasibhatla

Authors
  1. Martin G Sanda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohit Kasibhatla
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin G Sanda.

Ethics declarations

Competing interests

MG Sanda has declared that he has acted as a consultant for Amgen and GTx. M Kasibhatla declared no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sanda, M., Kasibhatla, M. Is androgen suppression therapy associated with early onset of fatal myocardial infarction?. Nat Rev Urol 5, 184–185 (2008). https://doi.org/10.1038/ncpuro1076

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro1076

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing